| scholarly article | Q13442814 |
| P2093 | author name string | S. Johansson | |
| G. Lindstedt | |||
| P. A. Lundberg | |||
| P. O. Janson | |||
| A. Odén | |||
| E. Dahlgren | |||
| F. Knutsson | |||
| N. Crona | |||
| L. A. Mattson | |||
| P2860 | cites work | Polycystic ovaries--a common finding in normal women | Q34560172 |
| Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome | Q35200941 | ||
| Polycystic ovary syndrome: a changing perspective | Q38240681 | ||
| The polycystic ovary syndrome | Q40257920 | ||
| Serum androstanediol glucuronide concentrations in normal and hirsute women and patients with thyroid dysfunction | Q41420988 | ||
| Insulin resistance in nonobese patients with polycystic ovarian disease | Q42450227 | ||
| Low sex-hormone-binding globulin concentration as independent risk factor for development of NIDDM. 12-yr follow-up of population study of women in Gothenburg, Sweden. | Q51612365 | ||
| Insulin as a factor of increased androgen production in women with obesity and polycystic ovaries. | Q51627806 | ||
| The influence of androgens on insulin resistance. | Q51643388 | ||
| Endometrial carcinoma; ovarian dysfunction--a risk factor in young women | Q68037341 | ||
| Uterine growth in the follicular phase of spontaneous ovulatory cycles and during luteinizing hormone-releasing hormone-induced cycles in women with normal or polycystic ovaries | Q68123277 | ||
| Clinical usefulness of plasma androstanediol glucuronide measurements in women with idiopathic hirsutism | Q69400471 | ||
| The distribution of oestradiol in plasma in relation to uterine cross-sectional area in women with polycystic or multifollicular ovaries | Q69420149 | ||
| Familial clustering in the polycystic ovarian syndrome | Q69721724 | ||
| Polycystic ovarian disease | Q70543383 | ||
| Effect of androgen excess on inappropriate gonadotropin secretion as found in the polycystic ovary syndrome | Q70565384 | ||
| Lipid metabolism in women with polycystic ovary syndrome: possible implications for an increased risk of coronary heart disease | Q70798349 | ||
| Determinations of endogenous immunoreactive luteinizing hormone-releasing hormone in human plasma | Q71585850 | ||
| Chronic anovulation syndrome and associated neoplasia | Q71671324 | ||
| Plasma Precursors of Estrogen. I. Extent of Conversion of Plasma Δ4-Androstenedione to Estrone in Normal Males and Nonpregnant Normal, Castrate and Adrenalectomized Females | Q72245397 | ||
| Elevated bioactive luteinizing hormone in women with the polycystic ovary syndrome | Q72782118 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | polycystic ovary | Q5547896 |
| polycystic ovary syndrome | Q500816 | ||
| P304 | page(s) | 505-513 | |
| P577 | publication date | 1992-03-01 | |
| P1433 | published in | Fertility and Sterility | Q15724525 |
| P1476 | title | Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long-term follow-up focusing on natural history and circulating hormones | |
| P478 | volume | 57 |
| Q35992640 | A paradigm for finding genes for a complex human trait: polycystic ovary syndrome and follistatin |
| Q40252855 | Aspects of Cardiometabolic Risk in Women with Polycystic Ovary Syndrome |
| Q35560263 | Assessment and management of anovulatory infertility in polycystic ovary syndrome |
| Q93108051 | Blood pressure in postmenopausal women with a history of polycystic ovary syndrome |
| Q37361766 | Clinical review: Lifecycle of polycystic ovary syndrome (PCOS): from in utero to menopause. |
| Q26799566 | Complications and challenges associated with polycystic ovary syndrome: current perspectives |
| Q51587513 | Coronary Heart Disease Risk Factors in Women With Polycystic Ovary Syndrome |
| Q37482748 | Criteria for polycystic ovarian morphology in polycystic ovary syndrome as a function of age. |
| Q35906974 | Defining the role of bariatric surgery in polycystic ovarian syndrome patients |
| Q33587845 | Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline |
| Q36690960 | Diagnostic criteria for polycystic ovarian syndrome |
| Q37223571 | Does metformin affect ovarian morphology in patients with polycystic ovary syndrome? A retrospective cross-sectional preliminary analysis |
| Q36683768 | Environmental and genetic factors influence age at menarche in women with polycystic ovary syndrome |
| Q36327934 | Evidence for statin therapy in polycystic ovary syndrome |
| Q35924430 | Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. |
| Q56995376 | Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging |
| Q34255040 | Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging |
| Q27026188 | Executive summary of the Stages of Reproductive Aging Workshop +10: addressing the unfinished agenda of staging reproductive aging |
| Q44593820 | Expression of steroid receptors and proteins related to apoptosis in endometria of women with polycystic ovary syndrome |
| Q37126371 | Familial associations between polycystic ovarian syndrome and common diseases |
| Q48820912 | Formation and early development of follicles in the polycystic ovary |
| Q26745164 | Genetic Rodent Models of Obesity-Associated Ovarian Dysfunction and Subfertility: Insights into Polycystic Ovary Syndrome |
| Q38150697 | Glucose intolerance states in women with the polycystic ovary syndrome |
| Q37253000 | HMG-CoA reductase inhibitors: do they have potential in the treatment of polycystic ovary syndrome? |
| Q39175827 | High androgen levels protect against hypothyroidism. |
| Q58591632 | Higher menopausal age but no differences in parity in women with polycystic ovary syndrome compared with controls |
| Q77694130 | How actual is the dietary treatment in overweighting patients with polycystic ovary syndrome? |
| Q35205039 | Implications for reproductive medicine: Sex differences in cardiovascular disease |
| Q35087405 | Insulin resistance and polycystic ovary syndrome |
| Q33569169 | Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications |
| Q33781663 | Insulin resistance, polycystic ovary syndrome and metformin |
| Q36690975 | Insulin resistance, the metabolic syndrome, diabetes, and cardiovascular disease risk in women with PCOS. |
| Q35751121 | Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus |
| Q35564923 | Insulin-Lowering Agents in the Management of Polycystic Ovary Syndrome |
| Q34181522 | Irregular menstruation and hyperandrogenaemia in adolescence are associated with polycystic ovary syndrome and infertility in later life: Northern Finland Birth Cohort 1986 study |
| Q27006736 | Is AMH a regulator of follicular atresia? |
| Q21296837 | Mediators of inflammation in polycystic ovary syndrome in relation to adiposity |
| Q33782970 | Obstetric and Neonatal Outcome in PCOS with Gestational Diabetes Mellitus |
| Q34536081 | Obstructive sleep apnea and metabolic dysfunction in polycystic ovary syndrome |
| Q57458409 | Ovarian and Extra-Ovarian Mediators in the Development of Polycystic Ovary Syndrome |
| Q35660296 | Ovarian hypertension: polycystic ovary syndrome |
| Q38755740 | Overexpression of Lnk in the Ovaries Is Involved in Insulin Resistance in Women With Polycystic Ovary Syndrome |
| Q90115180 | PCOS and Hyperprolactinemia: what do we know in 2019? |
| Q36666354 | Polycystic Ovary Syndrome and Obstructive Sleep Apnea |
| Q33723471 | Polycystic ovarian syndrome: diagnosis and management |
| Q33791299 | Polycystic ovarian syndrome: the metabolic syndrome comes to gynaecology |
| Q77694096 | Polycystic ovary syndrome and insulin resistance: thrifty genes struggling with over-feeding and sedentary life style? |
| Q33781680 | Prevention of type 2 diabetes: role of metformin. |
| Q51391379 | Relation between C-reactive protein and body mass index in patients with polycystic ovarian syndrome |
| Q37410552 | Relationship between IL-17 serum level and ambulatory blood pressure in women with polycystic ovary syndrome |
| Q37445314 | Serum C-reactive protein levels in normal-weight polycystic ovary syndrome |
| Q33789151 | Statins in the treatment of polycystic ovary syndrome |
| Q35661747 | Sustained fertility from 22 to 41 years of age in women with polycystic ovarian syndrome |
| Q35819237 | The clinical biochemistry of obesity. |
| Q36472269 | The metabolic syndrome in polycystic ovary syndrome |
| Q35544333 | The prevalence of idiopathic hirsutism and polycystic ovary syndrome in the Tehran Lipid and Glucose Study |
| Q35649437 | Treatment of PCOS with metformin and other insulin-sensitizing agents |
| Q79160358 | Ultrasound diagnosis of polycystic ovaries in women who have no symptoms of polycystic ovary syndrome is not associated with subfecundity or subfertility |
| Q35583311 | Vascular effects of estrogenic menopausal hormone therapy |
Search more.